secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vivani Medical, Inc. (VANI)
CIK:        0001266806
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001753926-25-001768
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vivani Medical Q3 net loss $6.5M; plans Phase 1 semaglutide implant study in H1 2026
--------------------------------------------------------------------------------

- Net loss of $6.5M in Q3 2025 vs $6.0M in Q3 2024; cash down to $4.0M from $19.7M at year-end 2024.
- Closed ~$15.7M in October equity financings and $10M August private placement, total $25.7M cash and commitments.
- Plans to initiate Phase 1 clinical study of NPM-139 semaglutide implant for chronic weight management in first half 2026.
- Spin-off of Cortigent temporarily withdrawn due to U.S. government shutdown; new record date expected after SEC resumes.
- R&D expense $4.5M ($4.2M in Q3 2024); G&A $2.2M ($2.1M in Q3 2024); operating expenses increased $0.4M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625001768/0001753926-25-001768-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1266806/000175392625001768/vani-20251113.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-001768

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer